Highlights from Q2 and 6 months 2023
- ArcticZymes Technologies (AZT) had Q2 sales of NOK 28.2 million (Q2 2022: NOK 30.4 million) and sales for the first 6 months of NOK 59.4 million (6M 2022: NOK 79.5 million, NOK 65.5 million adjusted for Covid effects in 1H 2022).
- AZT had a positive EBITDA for Q2 of NOK 6.8 million (Q2 2022: NOK 9.5 million) and a positive EBITDA for the first 6 months of NOK 13.0 million (6M 2022: NOK 37.4 million and NOK 23.4 million adjusted for Covid effects in 1H 2022).
- Operating expenses for Q2 were 21.4 million (Q2 2022: NOK 20.8 million) and for the first 6 months expenses were NOK 46.4 million (6M 2022: NOK 42.1 million).
- Cash flow for Q2 was positive NOK 7.3 million (Q2 2022: NOK 16.4 million) and NOK -4.4 million (6M 2022: NOK 30.6 million) for the first six months of 2023, giving a cash balance of NOK 239.8 million.
- Hired Michael Akoh as new CEO with starting date on 18 September 2023.
- Filed the Drug Master File (DMF) for SAN HQ GMP
Chairman of the Board Marie Roskrow comments:
“With continuing headwinds in the markets, both macroeconomic and sector-specific, it is proving to be a tough year for sales so far. Our Q2 revenues and EBITDA were very similar to those of Q1 but positive progress was seen in all other areas of the business. Critically, we hired a CEO with a strategic mindset and a wealth of commercial experience to take AZT to the next level of excellence.
Additionally, we filed our first DMF for the SAN HQ GMP product on schedule, launched another enzyme to the market and expanded our senior management team to cover corporate development and regulatory affairs.”
